Alto Neuroscience, Inc. (NYSE: ANRO) Targets Significant Growth in Neuropsychiatric Treatment

Core Insights - Alto Neuroscience, Inc. is a clinical-stage biopharmaceutical company focused on developing precision medicines for neuropsychiatric disorders, aiming to address unmet needs in mental health treatment through innovative therapies [1][6] - The company recently secured approximately $120 million through private placement financing, which is expected to support the advancement of its treatment pipeline for neuropsychiatric conditions [2][6] - Jefferies analyst Andrew Tsai set a price target of $35 for ANRO, indicating a potential upside of 41.24% from its current trading price [1][6] Financial Performance - ANRO's stock is currently priced at $24.43, reflecting a notable increase of 9.75% with a change of $2.17, reaching a year-high of $24.94 [3][6] - The stock's market capitalization stands at approximately $759 million, with a trading volume of 512,010 shares, indicating active investor engagement [4] - The lowest stock price over the past year was $1.60, showcasing significant growth for the company [5]